The present invention provides use of soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig in the treatment of immune disorders associated with graft transplantation.

 
Web www.patentalert.com

< Fungicides compositions comprising the extract of Chloranthus henryi and a novel sesquiterpene compound isolated from them

> Compositions and methods for treating and preventing virus infections
~ 00493